Novo Nordisk

Novo Nordisk today presented new sub-analyses from the phase 3 OASIS 4 clinical trial at the European Congress on Obesity 2026 (ECO2026) in Istanbul, Turkey, showing how well Wegovy® pill (oral semaglutide 25 mg) works in adults living with obesity compared with placebo1,2. The new findings show that nearly one in three adults (28.8%) who responded early to the Wegovy® pill – meaning ≥10% weight loss by week 16 – achieved 13.2% weight loss by week 16 of treatment1. This group of Wegovy® pill early responders went on to achieve ...